Meeting Information - The shareholders' meeting is scheduled for September 12, 2025, at 14:00 [1] - The meeting will be held at the company's conference room located at 385 Hui Rong Road, Jiading Industrial Zone, Shanghai [1] - Voting will be conducted through a combination of on-site and online methods [1] Voting Procedures - The online voting system used will be the Shanghai Stock Exchange shareholders' meeting online voting system [2] - Voting will be available from 9:15 to 15:00 on the day of the meeting [1][2] - Shareholders must complete identity verification to vote via the internet [2] Agenda Items - The meeting will review several proposals, including the management assessment method and matters related to the restricted stock incentive plan [2] - All proposals have been approved by the company's board meeting held on August 22, 2025 [2] Attendance Requirements - Shareholders registered by the close of trading on September 5, 2025, are eligible to attend the meeting [4] - Shareholders can appoint a proxy to attend and vote on their behalf [4] Registration Details - Registration for the meeting will take place on September 8, 2025, from 9:00 to 17:00 [5] - Registration can be done via mail or fax, and must be completed by the specified deadline [5] Contact Information - For inquiries, shareholders can contact Ms. Wang at 021-58266088 [5]

东方证券股份有限公司 关于上海三友医疗器械股份有限公司 使用部分闲置募集资金暂时补充流动资金的 核查意见 东方证券股份有限公司（以下简称"东方证券"或"独立财务顾问"）作为 上海三友医疗器械股份有限公司（以下简称"三友医疗"或"公司"）发行股份 及支付现金购买资产并募集配套资金暨关联交易的独立财务顾问，根据《证券发 行上市保荐业务管理办法》 《上市公司募 集资金监管规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规 《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等法律 范运作》 法规的相关规定，对三友医疗本次拟使用部分闲置募集资金暂时补充流动资金事 项进行了专项核查，具体核查情况如下： 一、募集资金基本情况 经上海证券交易所并购重组审核委员会 2024 年 12 月 30 日审核同意，并经 中国证券监督管理委员会于 2025 年 1 月 17 日《关于同意上海三友医疗器械股份 有限公司发行股份购买资产并募集配套资金注册的批复》 （证监许可〔2025〕109 号）同意注册，公司获准向特定对象发行人民币普通股 13,032,886 股，每股面值 人民币 1.00 元，每股发行价为人民 ...

Core Viewpoint - Shanghai Sanyou Medical Devices Co., Ltd. has announced a stock incentive plan to grant 4.782 million restricted stocks, accounting for 1.43% of the company's total share capital, aimed at attracting and retaining talent while aligning the interests of shareholders, the company, and core team members [1][3][4]. Group 1: Incentive Plan Overview - The incentive plan involves granting restricted stocks as a means of employee motivation [3][4]. - The total number of restricted stocks to be granted is 4.782 million, which is approximately 1.43% of the company's total share capital of 333.462498 million shares [1][4]. - The stocks will be sourced from shares repurchased from the secondary market or newly issued shares directed to the incentive recipients [3][4]. Group 2: Eligibility and Distribution - The incentive recipients include 55 individuals, primarily directors, senior management, and key personnel, excluding independent directors [5][6]. - The distribution of restricted stocks among recipients is structured, with specific allocations for directors and senior management [5][6]. Group 3: Granting and Vesting Conditions - The grant price for the restricted stocks is set at 11.12 yuan per share, which is based on a formula ensuring it is not lower than the stock's par value or a percentage of the average trading price prior to the announcement [10][11]. - The vesting of the stocks is contingent upon meeting performance targets related to revenue growth, with specific thresholds set for the years 2025 and 2026 [14][16]. Group 4: Performance Assessment - The performance assessment will be conducted annually, with the first assessment in 2025 and the second in 2026, based on the company's revenue growth rate [14][16]. - The plan includes a dual-layer assessment: company-level performance and individual performance, which will determine the actual number of stocks vested to each recipient [16][17]. Group 5: Legal and Procedural Framework - The plan adheres to relevant laws and regulations, including the Company Law and Securities Law, and requires approval from the board and shareholders [2][3][5]. - The implementation of the plan involves a series of procedural steps, including public disclosure and legal opinions from independent advisors [18][19].

证券简称：三友医疗 证券代码：688085 独立财务顾问报告 目 录 一、释义 ·························································································· 3 二、声明 ·························································································· 4 三、基本假设 ···················································································· 5 四、独立财务顾问意见 ········································································ 6 （一） 对公司实行 2025 年限制性股票激励计划条件的核查意见 ················6 （二） 对 2025 年限制性股票激励计划内容及可行性的核查意见 ················7 ...

注：表格中部分合计数与各明细数直接相加之和在尾数上如有差异，是由于四舍五入所造成。 上海三友医疗器械股份有限公司董事会 | | | | | | 占本激励计 | | | --- | --- | --- | --- | --- | --- | --- | | | | | 获授的限制 | 占授予限制 | | | | 序 | | | | | 划草案公告 | | | 姓名 国籍 | | 职务 | 性股票数量 | | 性股票总数 | | | 号 | | | | | 日公司股本 | | | | | | （万股） | 的比例 | | | | 一、董事、高级管理人员 | | | | | 总额的比例 | | | | 董事、副总裁、首席运 | | | | | | | | 营官 | | | | | | | 董事、高级管理人员小计 | | | | 45.00 | 9.41% | 0.13% | | 二、其他激励对象 | | | | | | | | 核心骨干人员 | | | | | | | （共 53 人） 合计 478.20 100.00% 1.43% 上海三友医疗器械股份有限公司 ...

Group 1 - The company Huayang Intelligent announced a provision for asset impairment of 4.1513 million yuan, which will lead to a reduction in total profit by the same amount for the first half of 2025 [1] - The company's revenue composition for the year 2024 is as follows: motor manufacturing accounts for 88.41%, medical devices for 7.6%, and other businesses for 3.99% [1]

Core Points - The company is holding its second extraordinary general meeting of shareholders in 2025 to discuss key proposals, including the employee stock ownership plan and daily related transactions [1][4][8] Group 1: Meeting Details - The meeting is scheduled for September 4, 2025, at 14:30, located at the company's office in Chongqing [4] - The meeting will be conducted both in-person and online, with specific voting times outlined for shareholders [4] - The agenda includes the introduction of attendees, discussion of proposals, and voting on the resolutions [4][8] Group 2: Proposal on Employee Stock Ownership Plan - The company proposes to repurchase and cancel 1,715,024 shares from the 2024 employee stock ownership plan due to unmet performance conditions [8][10] - The repurchase price is set at 8.23 yuan per share, adjusted from the original price of 12.27 yuan per share [10][11] - The funding for the repurchase will come from the company's own funds, and the cancellation will not affect the control of the company [11][12] Group 3: Daily Related Transactions - The company plans to increase the expected amount for daily related transactions in 2025, with a total expected amount of 5,990 million yuan [6][8] - The increase is primarily due to the need to meet procurement demands from related parties [6][7] - The transactions will adhere to fair market pricing principles and will not harm the interests of shareholders [7][8]

西部证券股份有限公司 关于重庆山外山血液净化技术股份有限公司 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市 规则》和《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有 关法律、法规的规定，西部证券股份有限公司（以下简称"保荐人"）作为重庆 山外山血液净化技术股份有限公司（以下简称"山外山"、"公司"）持续督导工 作的保荐人，负责山外山上市后的持续督导工作，并出具本持续督导跟踪报告。 一、持续督导工作情况 序号 工作内容 持续督导情况 保荐人己建立健全并有效执行了 建立健全并有效执行持续督导工作制度，并针 对具体的持续督导工作制定相应的工作计划 工作计划 根据中国证监会相关规定，在持续督导工作开 保荐人己与山外山签订《保荐协 始前，与上市公司签署持续督导协议，明确双 议》，该协议明确了双方在持续督 方在持续督导期间的权利义务，并报上海证券 导期间的权利和义务，并报上海 交易所备案 证券交易所备案 保荐人通过日常沟通、定期或不 通过日常沟通、定期回访、现场检查、尽职调 定期回访、现场检查等方式，了解 查等方式开展持续督导工作 山外山业务情况，对山外山开展 持续督导工作 持续督 ...

Core Viewpoint - The report outlines the ongoing supervision and assessment of Hangzhou Anjisi Medical Technology Co., Ltd. by CITIC Securities, focusing on the company's compliance, financial performance, and potential risks in the medical device industry [1][2]. Group 1: Continuous Supervision Overview - CITIC Securities conducted a site inspection on July 14, 2025, as part of its ongoing supervisory responsibilities [1]. - The supervision included reviewing corporate governance documents, financial management systems, and fundraising management practices [1]. Group 2: Identified Issues and Rectification - No major issues were found during the supervision period, indicating effective management practices [2]. - The company faces core competitiveness risks due to the lengthy and complex nature of developing minimally invasive endoscopic devices [2][3]. Group 3: Major Risk Factors - The company is exposed to operational risks from increasing competition in the domestic market and potential price reductions due to healthcare cost control measures [2][4]. - Quality control is critical, as any product defects could harm the company's reputation and financial performance [3][4]. Group 4: Financial Performance - For the first half of 2025, the company reported a revenue of 302.43 million yuan, a 14.56% increase from the previous year [11]. - The total profit for the same period was 149.13 million yuan, reflecting a 2.78% increase [11]. - The net profit attributable to shareholders was 111.51 million yuan, showing a decrease of 7.06% when excluding non-recurring gains [11]. Group 5: Research and Development - The company has increased its R&D investment, with total R&D expenses reaching 34.46 million yuan, a 33.29% increase compared to the previous period [18]. - R&D efforts focus on innovative diagnostic and therapeutic devices, with a strong emphasis on integrating AI technologies [12][18]. Group 6: Market Dynamics - The company is expanding its market presence, with significant sales growth in Europe (38.28%) and Asia (29.05%), while facing a decline in North America (9.89%) due to trade tensions [16]. - The company actively adapts to new procurement policies and payment regulations in the healthcare sector to maintain competitiveness [8][9]. Group 7: Compliance and Governance - The company adheres to various international and domestic quality management standards, ensuring compliance in its operations [13]. - There were no significant violations of fundraising regulations during the supervision period, indicating sound financial governance [21][24].

本公司及董事会全体成员保证公告内容的真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 一、被实施其他风险警示暨可能被实施退市风险警示的相关情况 公司董事会对众华出具无法表示意见的内部控制审计报告涉及的事项高度 重视，积极采取相应的措施，尽快消除相关事项及其影响。结合公司的实际情况， 公司已采取和拟采取的措施如下： 证券代码：300326 证券简称：ST 凯利 公告编号：2025-084 上海凯利泰医疗科技股份有限公司 上海凯利泰医疗科技股份有限公司（以下简称"公司"）2024年度财务报告 内部控制被众华会计师事务所（特殊普通合伙）（以下简称"众华"）出具了无 法表示意见的审计报告。根据《深圳证券交易所创业板股票上市规则》（以下简 称"《创业板股票上市规则》"）第9.4条第（四）项规定，公司出现"（四） 最近一个会计年度财务报告内部控制被出具无法表示意见或者否定意见的审计 报告，或者未按照规定披露财务报告内部控制审计报告"的情形，公司股票交易 被深圳证券交易所实施其他风险警示；根据《深圳证券交易所创业板股票上市规 则》第 10.4.4 条第（五）项规定，上市公司出现"首个会计年度财务报告内部 控制被出具 ...